SWORD trial of d-sotalol [10]

Lancet

Volumn 348, Issue 9030, 1996, Pages 827-828

  Ghali, J K ^a   Tan, L B ^a   Waldo, A L ^a  

^a Louisiana Stt Univ Sch M   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SOTALOL; ANTIARRHYTHMIC AGENT; POTASSIUM CHANNEL;

HEART ARRHYTHMIA; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; NOTE;

ANTI-ARRHYTHMIA AGENTS; HUMANS; POTASSIUM CHANNELS; SOTALOL; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0041119408     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)65250-6     Document Type: Letter

References (3)

1. J Sanderson The SWORD of Damocles Lancet 348 1996 2 3
2. DS Echt PR Leibson LB Mitchell The CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
3. AL Waldo AJ Camm deRuyter H , for the SWORD investigators. Effect of f/-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction Lancet 348 1996 7 12